Logo image

Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Vienna General Hospital, Austria

Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Vienna General Hospital, Austria

Vienna, Austria

User ScoreRatingMedia Files


Age group


Type of care

Inpatient, Outpatient



About the offer

The main principle of Actinium-225 therapy is a point effect on prostate tumors and metastases. Cancer cells have many receptors for a particular protein — prostate-specific membrane antigen (PSMA) on their surface. The radioactive substance (Ac-225) attaches to the PSMA molecule, which finds prostate cancer. When approaching them, Actinium decays into alpha particles. They irradiate a cancer cell, tear its DNA and kill it. At the same time, there is no harmful effect on neighboring healthy cells due to the short range of alpha radiation - 0. 04 mm. Before the start of therapy, the patient undergoes a diagnosis. It includes a PSA test, PET-CT with gallium-68, and kidney and liver function assessment. The tests help the doctor to detect metastases and assess all the risks. The drug is injected intravenously for several minutes. Actinium-225 spreads through the body with blood flow and accumulates on cancer cells. The distribution of the radionuclide is controlled by scintigraphy. With this innovative therapies, tumor cells can be specifically targeted and healthy tissue can be spared at the same time. A therapy session and observation in a hospital take only a few days. After that, the patient returns to his daily life.

What’s included

Medical service

  • clinical history-taking
  • medical records review
  • physical examination
  • consultation with a nuclear medicine specialist
Laboratory tests
  • complete blood count (CBC)
  • biochemical analysis of blood (kidney and liver function tests, electrolytes)
  • inflammation blood tests
  • urinalysis
  • PSA test
  • Ga-68 PSMA PET CT scan (on the indication, price is not included)
  • renal scintigraphy with 99mTc-MAG3
  • pre-procedure patient preparation
  • 1 session of Actinium-225 PSMA-617 radioligand therapy
  • post-procedure care
  • control examinations
  • symptomatic treatment
  • cost of radiopharmaceuticals
  • cost of essential medicines
  • cost of essential materials
  • doctors' fee
  • hospitalization
  • nursing service
  • discharge medical records
  • further recommendations
Distant service
  • support after the therapy to evaluate the treatment results and subsequent blood tests

Extra add-ons

Local transportation
Airport transfer
Single room
Hospital meals
Personal coordinator


AiroMedical support
Payment protection
Patient advocacy
Price match

Meet the provider

Univ. Prof. Dr. med. Marcus Hacker

nuclear medicine and prostate cancer


Why to choose us?

Unique, specialized team
The Theranosticum Vienna, under the guidance of Univ.-Prof. Dr. Marcus Hacker, Univ.-Prof. Dr. Werner Langsteger, and Univ.-Prof. Mag. Markus Mitterhauser, specializes in nuclear medicine diagnostics and outpatient personalized therapies for various types of cancer. They are located at the Institute for Nuclear Medicine and Isotope Diagnostics at the Döbling Ambulatory and Vienna General Hospital for inpatient stay.
Personalized approach
The THERANOSTICS principle "we treat what we see" means that what was previously visible is treated. This principle enables a personalized therapy decision with radio ligand therapy, which is made exclusively in close coordination between the treating physician and the patient. Together, a suitable radiopharmaceutical is selected that binds selectively and with high precision to the surface of tumor cells, thus specifically destroying tumors and metastases while minimizing damage to the surrounding healthy tissue.
Life-changer for metastatic prostate cancer
The treatment can significantly increase the quality of life and extend the life span due to its good tolerability. Numerous studies have shown that it can produce good results, particularly in treating prostate cancer.


Customize this offer

If you're not seeing exactly what you need here, send your custom request. You can discuss the content, specifics, price & timeline to create a personalized plan.


Währinger Gürtel, 18-20, 1090 Vienna Austria


What is the cost?

The total price for Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Vienna General Hospital, Austria is €28,965. However, it can vary from the specifics of each case. Get in touch to get an individual estimate.

What is the rating of the offer?

Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Vienna General Hospital, Austria is rated as 9.80 by AiroMedical.

Who is offering a deal?

How long does the offer take?

The offer is designed for 4 days.

Does the offer require you to stay in the clinic overnight?

Actinium 225 PSMA Radioligand Therapy for Prostate Cancer - 1 cycle | Vienna General Hospital, Austria requires a mixed stay. Therefore, some parts of the offer are carried out on an outpatient basis. At the same time, some parts might require hospitalization.

What are the age restrictions?

The offer is eligible only for adults.

Can I customize the content of the offer?

Yes, the components of the deal can be changed. Get in touch with a vendor to create a personalized proposal.

Does the offer include extra services?

Individual cost estimate. Non-binding 100% free assessment.


Similar deals